Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. - Wikidata - awgldk - TriplyDB

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

http://www.wikidata.org/entity/Q37743492

about

Ustekinumab: differential use in psoriasis Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.

P2860

Q35096980-F6A8FB81-AFB6-4C78-8F6A-024112992CD4 Q38920742-5B719081-90FA-410B-8C56-408B1D78ED4B Q39048706-B3DA7BB8-7305-4E7F-94B1-8EEE7C6D3A14 Q42635096-ED4CACA9-9C38-4209-BF8C-FF600B3CF78F

P2860

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

http://www.wikidata.org/entity/Q37743492

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@en

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@nl

type

label

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@en

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@nl

prefLabel

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@en

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@nl

P1433

Q37743492-E3DF917A-A363-46CC-9DBC-9D01CF225CB3

P1476

Q37743492-E30D4205-A3D2-4B66-8FA3-FDB240AC80E5

P2093

Q37743492-7E37AAB4-A628-4857-BC08-532881CA1858

Q37743492-C72A2923-C770-412C-AD2E-5AC38B9A958D

P2860

Q37743492-0089ED61-22D6-45B7-965A-403A6321DA1A

Q37743492-056009D3-CF9B-4A2A-8B08-510DD1C2CD6F

Q37743492-0AB04FD1-319B-434C-BD52-15DBA2A9BE45

Q37743492-0AC74C36-7670-4B6D-B1C2-9CCCF458E010

Q37743492-0DF10916-7744-4AA3-9C41-F2DA16A97C97

Q37743492-1A48013C-02FE-47A1-8C40-D412AE521312

Q37743492-20E0B1C4-2D8A-451A-BC74-2A49C3F852F5

Q37743492-2B51E98F-382F-4232-AAE8-CB6AA988707B

Q37743492-3387B8CD-50E4-4DAA-BFF7-FB1DE32904B7

Q37743492-35A8E23B-AE00-463E-8378-5D3C5966C945

P304

Q37743492-E791F877-554C-4E3D-A128-5AF60A49C7EB

P31

Q37743492-5DD53557-7423-4C09-A567-04617BF2D5A6

P356

Q37743492-3DC851EB-8519-4A64-9F73-044EC33CF465

P407

Q37743492-AD844805-375A-422A-A7F3-F2CA3DFAE01C

P433

Q37743492-E51584E8-734C-490F-89B4-4B42FC0B3558

P478

Q37743492-989F662E-7730-4D02-90EC-93074FB7DEED

P577

Q37743492-918AB5C5-84D2-469A-97EC-B22D87F0147A

P698

Q37743492-50C18D7B-70B2-4947-8E42-ED39DB8C142B

P356

14712598.2010.487061

P1433

Expert Opinion on Biological Therapy

P1476

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

@en

P2093

Elizabeth E Uhlenhake

http://www.w3.org/2001/XMLSchema#string

Steven R Feldman

http://www.w3.org/2001/XMLSchema#string

P2860

Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

P304

1105-1112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2010.487061

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20446825

http://www.w3.org/2001/XMLSchema#string